temozolomide has been researched along with vx-970 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, F; Dubois, LJ; Lambin, P; Niemans, R; Parvathaneni, NK; Pastorekova, S; Supuran, CT; van Gisbergen, MW; van Kuijk, SJA; Vullo, D; Winum, JY; Yaromina, A | 1 |
| Bindra, RS; Breslin, H; Burgenske, DM; Ganesa, S; Gilad, O; Jackson, CB; Jia, L; Kalathil, AN; Noorbakhsh, SI; Sarkaria, JN; Sundaram, RK | 1 |
2 other study(ies) available for temozolomide and vx-970
| Article | Year |
|---|---|
New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Dogs; Drug Design; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Madin Darby Canine Kidney Cells | 2017 |
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Female; Humans; Isoxazoles; Mice, Nude; Pyrazines; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |